Screener
Quest Diagnostics DGX Balance Sheet Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $626M+96.2% | $393M+109% | $420M-23.5% | $432M-43.5% | $319M+17.7% | ||
| $1.67B+17.4% | $1.59B+13.0% | $1.41B+8.0% | $1.46B+5.8% | $1.42B+7.6% | ||
| $233M+24.6% | $225M+19.0% | $189M+0.5% | $186M+1.1% | $187M+2.7% | ||
| $2.84B+29.4% | $2.57B+23.7% | $2.38B-0.6% | $2.41B-8.2% | $2.2B+9.0% | ||
| $2.22B+4.7% | $2.19B+4.3% | $2.2B+4.3% | $2.15B+2.5% | $2.12B+15.7% | ||
| $9.11B+2.6% | $9.12B+3.1% | $8.95B+1.0% | $8.9B+3.4% | $8.88B+12.7% | ||
| $1.67B-2.0% | $1.72B-0.5% | $1.64B-7.2% | $1.66B-3.1% | $1.71B+41.9% | ||
| $16.94B+6.1% | $16.67B+5.5% | $16.23B+0.4% | $16.2B+0.6% | $15.97B+15.0% | ||
| $1.6B+18.5% | $1.5B+18.4% | $1.6B+14.8% | $1.46B+11.0% | $1.35B+8.2% | ||
| $10M-98.0% | $503M+50,200% | $504M-16.3% | $504M-16.4% | $504M-16.8% | ||
| $1.79B-11.7% | $2.18B+51.1% | $2.28B+5.0% | $2.13B+2.0% | $2.02B+0.6% | ||
| $5.63B+9.0% | $5.16B-12.0% | $5.17B-8.0% | $5.17B-8.4% | $5.17B+35.5% | ||
| $2M0.0% | $2M0.0% | $2M0.0% | $2M0.0% | $2M0.0% | ||
| $10.37B+7.1% | $10.15B+7.0% | $9.99B+6.8% | $9.84B+6.7% | $9.68B+6.6% | ||
| $7.52B+4.0% | $7.37B+6.3% | $7.17B+5.8% | $7.26B+6.6% | $7.23B+9.2% | ||
| $16.94B+6.1% | $16.67B+5.5% | $16.23B+0.4% | $16.2B+0.6% | $15.97B+15.0% |
FAQ
- What are Quest Diagnostics's total assets?
- Quest Diagnostics (DGX) holds $16.9B in total assets, up 6.1% year over year.
- How much debt does Quest Diagnostics have?
- Quest Diagnostics carries $6.4B in total debt against $7.5B of shareholders' equity, a debt-to-equity ratio of 0.85.
- How much cash does Quest Diagnostics have?
- Quest Diagnostics holds $626.0M in cash and equivalents.
- Can Quest Diagnostics cover its short-term obligations?
- Its current ratio is 1.59 — current assets exceed current liabilities.
- Where does Quest Diagnostics's balance sheet data come from?
- Every line is extracted from Quest Diagnostics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
